Displaying results 1 - 3 of 3
Clear search
Mestag Therapeutics appoints Dr. Matthew Sleeman as Chief Scientific Officer
Mestag Therapeutics, a biotech company harnessing fibroblast immunology for the benefit of patients with inflammatory disease and cancer, announces that Matthew Sleeman, PhD, has been appointed Chief Scientific Officer.
Mestag Therapeutics extends seed financing to $45 million and welcomes new investors
Mestag Therapeutics, a breakthrough inflammatory disease and immuno-oncology company, has announced the closing of its oversubscribed Seed extension, bringing the total Seed round to $45 million.
Newborn bio business Mestag Therapeutics raises $11m seed cash
A new Cambridge UK BioMedTech business fighting inflammatory disease and cancer has launched with $11 million seed cash from healthcare backers SV Health Investors and Johnson & Johnson Innovation.